<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="[OANC]/data/written_2/technical/biomed/1468-6708-3-10.anc" start="9460" end="9466" sStart="9247" offset="213" sid="r11.severe.j.0223" wn="5" wnkey="severe%5:00:00:critical:03" annotator="vebatchelder" text="Study guidelines caution against a hasty HF diagnosis in patients with severe pulmonary disease, including chronic obstructive pulmonary disease (COPD), pneumonia, or other severe, documented lung disease." />
    <s path="[OANC]/data/written_2/technical/biomed/1468-6708-3-10.anc" start="9338" end="9344" sStart="null" offset="91" sid="r11.severe.j.0222" wn="5" wnkey="severe%5:00:00:critical:03" annotator="adelpriore" text="Study guidelines caution against a hasty HF diagnosis in patients with severe pulmonary disease, including chronic obstructive pulmonary disease (COPD), pneumonia, or other severe, documented lung disease." />
    <s path="[OANC]/data/written_2/technical/biomed/1468-6708-3-10.anc" start="29103" end="29114" sStart="null" offset="307" sid="r11.recommend.v.0372" wn="1" wnkey="recommend%2:32:01::" annotator="adelpriore" text="2) The ALLHAT Manual of Operations provides for prescription of open-label medicines of the same class as the blinded medications, when a compelling indication exists, such that the total dose of the added open-label drug should not exceed 1/2 of the maximum dose as recommended in the Sixth Report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC VI)." />
    <s path="[OANC]/data/written_2/technical/biomed/1468-6708-3-10.anc" start="21557" end="21563" sStart="null" offset="312" sid="r9.level.n.0848" wn="2" wnkey="level%1:26:01::" annotator="brubin" text="The differences in eligibility risk factors between those participants with HF and those without is not surprising: larger percentages of those with HF had a history of MI, stroke, CABG, angioplasty, other atherosclerotic cardiovascular disease (ASCVD), diabetes, low HDL levels and ECG abnormalities." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1468-6708-3-10.anc" start="1408" end="1415" sStart="null" offset="0" sid="null" wn="2147483647" wnkey="null" annotator="carichter" text="Randomization to the hypertension component began in February, 1994, and continued through January, 1998, with 42,418 participants recruited at 623 clinical centers in the United States, Canada, Puerto Rico and the US Virgin &lt;b&gt;Islands&lt;/b&gt;." />
    <s path="[OANC]/data/written_2/technical/biomed/1468-6708-3-10.anc" start="21427" end="21434" sStart="null" offset="182" sid="r1.history.n.0094" wn="" wnkey="null" annotator="vebatchelder" text="The differences in eligibility risk factors between those participants with HF and those without is not surprising: larger percentages of those with HF had a history of MI, stroke, CABG, angioplasty, other atherosclerotic cardiovascular disease (ASCVD), diabetes, low HDL levels and ECG abnormalities." />
    <s path="[OANC]/data/written_2/technical/biomed/1468-6708-3-10.anc" start="21427" end="21434" sStart="null" offset="182" sid="r1.history.n.0094" wn="1" wnkey="history%1:28:00::" annotator="sophiavv" text="The differences in eligibility risk factors between those participants with HF and those without is not surprising: larger percentages of those with HF had a history of MI, stroke, CABG, angioplasty, other atherosclerotic cardiovascular disease (ASCVD), diabetes, low HDL levels and ECG abnormalities." />
    <s path="[OANC]/data/written_2/technical/biomed/1468-6708-3-10.anc" start="21427" end="21434" sStart="null" offset="182" sid="r1.history.n.0094" wn="1" wnkey="history%1:28:00::" annotator="anfahmy" text="The differences in eligibility risk factors between those participants with HF and those without is not surprising: larger percentages of those with HF had a history of MI, stroke, CABG, angioplasty, other atherosclerotic cardiovascular disease (ASCVD), diabetes, low HDL levels and ECG abnormalities." />
    <s path="[OANC]/data/written_2/technical/biomed/1468-6708-3-10.anc" start="21427" end="21434" sStart="null" offset="182" sid="r1.history.n.0094" wn="2147483646" wnkey="null" annotator="adelpriore" text="The differences in eligibility risk factors between those participants with HF and those without is not surprising: larger percentages of those with HF had a history of MI, stroke, CABG, angioplasty, other atherosclerotic cardiovascular disease (ASCVD), diabetes, low HDL levels and ECG abnormalities." />
    <s path="[OANC]/data/written_2/technical/biomed/1468-6708-3-10.anc" start="23312" end="23320" sStart="null" offset="130" sid="r11.function.n.0924" wn="2" wnkey="function%1:07:00::" annotator="adelpriore" text="However, HF is a clinical diagnosis that does not necessarily exclude those with intact left ventricular systolic function [ 11 ] . Hypertension is a major risk factor for diastolic HF; as many as 25% of asymptomatic hypertensives with left ventricular hypertrophy have diastolic dysfunction." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1468-6708-3-10.anc" start="27158" end="27166" sStart="null" offset="0" sid="null" wn="4" wnkey="exercise%1:04:01::" annotator="veweser" text="This validation &lt;b&gt;exercise&lt;/b&gt; further illustrates the ability of large, simple trials to answer important public health questions requiring large sample sizes and to grapple with unexpected results in a responsible and meaningful manner." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1468-6708-3-10.anc" start="27158" end="27166" sStart="null" offset="0" sid="null" wn="4" wnkey="exercise%1:04:01::" annotator="jeneale" text="This validation &lt;b&gt;exercise&lt;/b&gt; further illustrates the ability of large, simple trials to answer important public health questions requiring large sample sizes and to grapple with unexpected results in a responsible and meaningful manner." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1468-6708-3-10.anc" start="27158" end="27166" sStart="null" offset="0" sid="null" wn="1" wnkey="physical_exercise%1:04:00::" annotator="cgozo" text="This validation &lt;b&gt;exercise&lt;/b&gt; further illustrates the ability of large, simple trials to answer important public health questions requiring large sample sizes and to grapple with unexpected results in a responsible and meaningful manner." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1468-6708-3-10.anc" start="27158" end="27166" sStart="null" offset="0" sid="null" wn="4" wnkey="exercise%1:04:01::" annotator="brubin" text="This validation &lt;b&gt;exercise&lt;/b&gt; further illustrates the ability of large, simple trials to answer important public health questions requiring large sample sizes and to grapple with unexpected results in a responsible and meaningful manner." />
    <s path="[OANC]/data/written_2/technical/biomed/1468-6708-3-10.anc" start="1667" end="1672" sStart="null" offset="72" sid="r10.board.n.0735" wn="1" wnkey="board%1:14:00::" annotator="cgozo" text="Following independent reviews by the Data and Safety Monitoring Board (DSMB) on January 6, 2000, and by an Ad Hoc Committee on January 21, 2000, the Director of the National Heart, Lung, and Blood Institute accepted a recommendation to discontinue the doxazosin treatment arm of the antihypertensive trial." />
    <s path="[OANC]/data/written_2/technical/biomed/1468-6708-3-10.anc" start="2024" end="2031" sStart="null" offset="82" sid="r11.benefit.n.0360" wn="2" wnkey="benefit%1:07:00::" annotator="adelpriore" text="This recommendation was based on the low probability of doxazosin showing benefit over chlorthalidone for the primary endpoint, as well as the significantly increased occurrence of the secondary endpoint, combined cardiovascular disease (CVD) (encompassing CHD deaths, nonfatal MI, stroke, coronary revascularization procedures [coronary artery bypass graft or CABG, percutaneous transluminal coronary angioplasty or PTCA/stent], angina [hospitalized or treated as an outpatient], heart failure [HF/treated in the hospital or as an outpatient], and peripheral arterial disease [in-hospital or outpatient revascularization]) in the doxazosin arm (RR 1.25; 95% CI, 1.17-1." />
  </sentences>
</list>